Pembrolizumab plus enfortumab vedotin in urothelial cancer

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY Nature Reviews Urology Pub Date : 2024-01-24 DOI:10.1038/s41585-024-00858-y
Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
{"title":"Pembrolizumab plus enfortumab vedotin in urothelial cancer","authors":"Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt","doi":"10.1038/s41585-024-00858-y","DOIUrl":null,"url":null,"abstract":"The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00858-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pembrolizumab+enfortumab vedotin治疗尿路癌。
作为晚期尿路上皮癌的一线疗法,pembrolizumab 和 enfortumab vedotin 的联合疗法前景看好。Enfortumab vedotin以nectin-4为靶点,进而增强T细胞和自然杀伤细胞的活性,抑制免疫抑制通路,阻碍肿瘤逃避。这种与 pembrolizumab 的协同作用显示了为这些患者加强免疫疗法的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
期刊最新文献
Prostate cancer in transgender women — challenges in research and clinical care Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer 20 years of ‘spilling the tea’ in urology Author Correction: Metaverse in surgery - origins and future potential. Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1